Leonard S. Schleifer
Net Worth

Last updated:

What is Leonard S. Schleifer net worth?

The estimated net worth of Dr. Leonard S. Schleifer is at least $593,551,123 as of 17 May 2024. He owns shares worth $268,356,231 as insider, has earned $207,494,892 from insider trading and has received compensation worth at least $117,700,000 in Regeneron Pharmaceuticals, Inc..

What is the salary of Leonard S. Schleifer?

Dr. Leonard S. Schleifer salary is $5,350,000 per year as Co-Founder, Pres, Chief Executive Officer & Executive Director in Regeneron Pharmaceuticals, Inc..

How old is Leonard S. Schleifer?

Dr. Leonard S. Schleifer is 72 years old, born in 1953.

What stocks does Leonard S. Schleifer currently own?

As insider, Dr. Leonard S. Schleifer owns shares in one company:

Company Title Shares Price per share Total value
Regeneron Pharmaceuticals, Inc. (REGN) Co-Founder, Pres, Chief Executive Officer & Executive Director 466,877 $574.79 $268,356,231

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN logo
REGN
Regeneron Pharmaceuticals, Inc.
$574.79

Leonard S. Schleifer insider trading

Regeneron Pharmaceuticals, Inc.

Dr. Leonard S. Schleifer has made 43 insider trades between 2003-2024, according to the Form 4 filled with the SEC. Most recently he sold 22,687 units of REGN stock worth $22,215,564 on 17 May 2024.

The largest trade he's ever made was exercising 520,313 units of REGN stock on 19 Nov 2021. As of 17 May 2024 he still owns at least 466,877 units of REGN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 22,687 $979.22 $22,215,564
Sale
Common Stock 143 $980.07 $140,150
Sale
Common Stock 228 $987.46 $225,141
Sale
Common Stock 235 $982.66 $230,925
Sale
Common Stock 250 $983.91 $245,978
Sale
Common Stock 305 $984 $300,120
Sale
Common Stock 281 $985.72 $276,987
Sale
Common Stock 103 $986.57 $101,617
Sale
Common Stock 299 $988.76 $295,639
Sale
Common Stock 7,864 $979.05 $7,699,249
Sale
Common Stock 295 $980.64 $289,289
Sale
Common Stock 1,081 $981.5 $1,061,002
Sale
Common Stock 22,698 $979.16 $22,224,974
Sale
Common Stock 2,302 $980.1 $2,256,190
Option
Common Stock 203,204 $399.66 $81,212,511
Option
Non-Qualified Stock Option (right to buy) 203,204 $399.66 $81,212,511
Option
Common Stock 25,155 N/A N/A
Option
2019 Performance Stock Units 25,155 N/A N/A
Sale
Common Stock 2,653 $710.04 $1,883,736
Sale
Common Stock 4,461 $710.05 $3,167,533
Sale
Common Stock 2,886 $710.01 $2,049,089
Option
Common Stock 520,313 $224.78 $116,955,956
Option
Non-Qualified Stock Option (right to buy) 239,063 $270.43 $64,649,807
Sale
Common Stock 10,000 $660.03 $6,600,300
Sale
Common Stock 200,000 $650.03 $130,006,000
Sale
Common Stock 10,000 $622.54 $6,225,410
Option
Common Stock 400,000 $52.03 $20,812,000
Option
Common Stock 400,000 $52.03 $20,812,000
Option
Non-Qualified Stock Option (right to buy) 400,000 $52.03 $20,812,000
Sale
Common Stock 150,922 N/A N/A
Option
Common Stock 312,500 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 312,500 N/A N/A
Option
Common Stock 312,400 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 312,400 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 100 N/A N/A
Option
Common Stock 100 N/A N/A
Option
Common Stock 312,500 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 312,500 N/A N/A
Option
Common Stock 250,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 250,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 250,000 N/A N/A
Option
Common Stock 250,000 N/A N/A
Option
Common Stock 7,226 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 7,226 N/A N/A
Sale
Common Stock 1,500 N/A N/A
Sale
Common Stock 42,324 N/A N/A
Sale
Common Stock 3,493 N/A N/A
Sale
Common Stock 3,453 N/A N/A
Sale
Common Stock 69,112 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 250,000 N/A N/A
Option
Common Stock 256,808 N/A N/A
Sale
Common Stock 9,162 N/A N/A
Option
Common Stock 29,276 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 29,276 N/A N/A
Sale
Common Stock 102,949 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 218,389 N/A N/A
Option
Common Stock 218,389 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 100,000 N/A N/A
Sale
Common Stock 3,655 N/A N/A
Sale
Common Stock 4,662 N/A N/A
Sale
Common Stock 3,534 N/A N/A
Sale
Common Stock 69,003 N/A N/A
Sale
Common Stock 19,146 N/A N/A
Option
Common Stock 43,757 N/A N/A
Option
Non-Qualified Stock Option 43,757 N/A N/A
Sale
Common Stock 100,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 250,000 N/A N/A
Option
Common Stock 500,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 250,000 N/A N/A
Option
Common Stock 250,000 N/A N/A
Sale
Common Stock 7,400 N/A N/A
Option
Common Stock 150,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 150,000 N/A N/A
Option
Incentive Stock Option (right to buy) 31,611 N/A N/A
Option
Common Stock 31,611 N/A N/A
Sale
Common Stock 15,900 N/A N/A
Option
Non-Qualified Stock Options (right to buy) 73,010 N/A N/A
Option
Common Stock 73,010 N/A N/A
Option
Non-Qualified Stock Options (right to buy) 37,370 N/A N/A
Option
Common Stock 37,370 N/A N/A
Sale
Common Stock 53,986 N/A N/A
Option
Common Stock 150,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 150,000 N/A N/A
Sale
Common Stock 30,000 N/A N/A
Sale
Common Stock 30,000 N/A N/A
Sale
Common Stock 401 N/A N/A
Sale
Common Stock 700 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 80,000 N/A N/A
Option
Common Stock 80,000 N/A N/A
Option
Incentive Stock Option (right to buy) 26,990 N/A N/A
Option
Common Stock 26,990 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 125,000 N/A N/A
Option
Common Stock 125,000 N/A N/A